Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age12+
SponsorStanford University
About this trial
Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)
Eligibility criteria
Qualifiers
Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: >2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is >2.5 cm in short axis
Age ≥12
ECOG Performance Status 0-2
Disqualifiers
Prior radiation therapy to the tumor to be treated
Active pregnancy
Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma
Trial design
Treatments tested in this trial
- LATTICE Radiotherapy
- Standard radiotherapy
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov